Invention Grant
- Patent Title: Inhibitors of the CD95 signaling pathway for treatment of MDS
- Patent Title (中): 用于治疗MDS的CD95信号通路抑制剂
-
Application No.: US14415851Application Date: 2013-07-18
-
Publication No.: US09540431B2Publication Date: 2017-01-10
- Inventor: Harald Fricke , Michaela Fontenay , Claudia Kunz
- Applicant: APOGENIX GmbH
- Applicant Address: DE Heidelberg
- Assignee: Apogenix AG
- Current Assignee: Apogenix AG
- Current Assignee Address: DE Heidelberg
- Agency: Perkins Coie LLP
- Agent Viola T. Kung
- Priority: EP12176974 20120718
- International Application: PCT/EP2013/065245 WO 20130718
- International Announcement: WO2014/013036 WO 20140123
- Main IPC: A61K38/18
- IPC: A61K38/18 ; C07K14/705 ; C07K16/28 ; G01N33/68 ; A61K38/17 ; A61K45/06 ; A61K39/395
Abstract:
The present invention relates to inhibitors of the CD95 signaling pathway for the use in the treatment of Myelodysplastic Syndrom (MDS) wherein the MDS is selected from the IPSS low risk MDS subgroup and/or the IPSS intermediate-1 (int-1) risk MDS subgroup as well as a method for the diagnosis of MDS.
Public/Granted literature
- US20150166632A1 INHIBITORS OF THE CD95 SIGNALING PATHWAY FOR TREATMENT OF MDS Public/Granted day:2015-06-18
Information query
IPC分类:
